1005142-67-5

Upstream product

• 1005142-65-3 (1S,3'R,4'S,5'R,6'R)-3',4',5'-tri(acetoxy)-6'-acetoxymethyl-5-chloro-6-chloromethyl-3',4',5',6'-tetrahydro-spiro[isobenzofuran-1(3H),2'-[2H]pyran] 
• 63139-21-9 4-ethylphenylboronic acid 
• 108-24-7 acetic anhydride 
• 1005142-57-3 [4-(acetoxymethyl)-2-bromo-5-chlorophenyl]methyl acetate 
• 85072-44-2 1-bromo-4-chloro-2,5-dimethylbenzene 

Downstream Products

• 1005142-97-1 (1S,3'R,4'S,5'R,6'R)-3',4',5'-triacetoxy-6'-(acetoxymethyl)-6-[(4-ethylphenyl)methyl]-3',4',5',6'-tetrahydro-5-trimethylsilylethynyl-spiro[isobenzofuran-1(3H),2'-[2H]pyran] 
• 1005142-51-7 (1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-5-ethynyl-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol 
• 1395786-44-3 C₂₈H₃₀O₆ 
• 1415692-77-1 C₃₆H₃₈O₁₀ 
• 1415692-68-0 C₃₂H₃₄O₁₀ 
• 1415692-60-2 C₃₁H₃₆O₁₀ 

Relevant academic research and scientific papers

A new and improved process for C-aryl glucoside SGLT2 inhibitors

A practical and scalable synthesis of C-glycosides identified as highly potent sodium-dependent glucose transporter 2 (SGLT2) inhibitors is described. Highlights of the synthetic process are a concise, ten-step synthesis of a structurally complex active pharmaceutical ingredient from a known intermediate via a selective and quantitative addition of an aryl species to the Weinreb amide, and the isomers of undesired ortho-products were avoided during the preparation. The chemistry developed has been applied to prepare SGLT2 inhibitors without recourse to chromatography.

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes. In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition o

SUBSTITUTED SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES

The present invention provides a compound represented by Formula (II): wherein R1 is a chlorine atom, a fluorine atom, a methyl group or an ethynyl group; Ar is a group represented by the following Formula (a), Formula (b), Formula (c) or Formula (d): wherein R2 is a C1-6 alkyl group which may be substituted with one or more halogen atoms, a C1-6 alkoxy group which may be substituted with one or more halogen atoms, a C1-3 alkylthio group, a halogen atom, a C1-3 alkylcarbonyl group or a C2-5 alkynyl group which may be substituted with -OR4; R3 is a hydrogen atom or a C1-3 alkyl group; R4 is a hydrogen atom or a C1-3 alkyl group; provided that Ar is a group represented by Formula (a) when R1 is a fluorine atom, methyl group or an ethynyl group, and that R2 is methoxy group, an ethoxy group, an isopropyl group, a propyl group, a trifluoromethyl group, a trifluoromethoxy group, 2-fluoroethyl group or 1-propynyl group when R1 is a methyl group or a pharmaceutically acceptable salt or a solvate thereof and a pharmaceutical agent, a pharmaceutical composition and so on comprising the compound.